The Brunner Investment Trust PLC

Annual General Meeting April 2019

Lucy Macdonald Matthew Tillett







Value. Shared.




# 01 Portfolio Review





## Track record of performance




Source: AllianzGI UK/ DataStream, as at March 29, 2019, GBP. Total Return. Cumulative returns. Benchmark is 30% FTSE All-Share and 70% FTSE World (ex UK) Index (£), (was 50/50 up to 21/03/17). Past performance is not a reliable indicator of future results. This is no recommendation or solicitation to buy or sell any particular security.



# Consistent dividend growth

46 Years of Rising Dividends

- One of the sector's highest yielding trusts at 2.42%
- Pays out quarterly dividends
- Prudent capital allocation to ensure consistent dividend growth
- Strong revenue reserves of 25.4p per share
- Board is minded to grow the dividend in excess of inflation




Past performance is not a reliable indicator of future results. Source: AllianzGI, as at February 28, 2019.




## Reducing interest payments to boost dividend cover

Pro Forma Earnings per Share are 8.7% higher following debt refinancing



Providing more scope for dividend growth given already strong reserves



Calculations are based on historic reported earnings per share as at February 28, 2019. FDF and Fintrust refinancing uplifts are estimates not forecasts. Past performance is not a reliable indicator of future results. This is no recommendation or solicitation to buy or sell any particular security.



# 02


# Market Outlook and Positioning





## What deleveraging?

Global debt to GDP by sector



Global debt to GDP by region


Global leverage has risen for decades, fuelled by asymmetric monetary policy and financial market deregulation.

Source: Allianz Global Investors Global Economics & Strategy, BIS, Datastream, data as at Q1 2018



### Liquidity: central banks wait and see

#### Central bank liquidity stimulus peaked in 2018



Even after peak liquidity, the ECB and Bank of Japan have only slightly adjusted their accommodative monetary policy. The Federal Reserve may also close to the end of its hiking cycle and intends to stop quantitative tightening by September 2019.



# Quality rising in importance as liquidity recedes MSCI Quality vs. MSCI World – 5 years



**NB:** The MSCI Quality index aims to capture the performance of quality growth stocks by identifying stocks with high quality scores based on three main fundamental variables: high return on equity (ROE), stable year-over-year earnings growth and low financial leverage.


Source: Bloomberg, as of February 18, 2019. Past performance is not a reliable indicator of future results.



## Trade conflicts placing strain on the global economy

More than 1/3 of all US imports under threat of higher tariffs

Further trade conflict may spill over to the world economy




Trade conflicts are unlikely to cause a global recession on their own. But souring sentiment, disrupted supply chains and tighter financial conditions may do additional harm.

<sup>1</sup>In case of a 25% (instead of 10%) duty imposed on an additional 450bn USD worth of imports from China, the maximum average tariff rate would rise to 10.1% instead of 7.2%. Source: Allianz Global Investors Global Economics & Strategy, IMF, OECD, Bank of England, KPMG, U.S. International Trade Commission



### Growth: earnings revisions slowing

#### Earnings revisions momentum (ratio of up/down estimates, 3months moving average)



Source: Thomson Reuters Datastream, AllianzGI Economics & Strategy 1/24/2019


Analysts are reducing earnings estimates as US tax cut impact fades and leading indicators cool.

Source: AllianzGI Economics & Strategy, Past performance is not a reliable indicator of future results. Forecasts are not a reliable indicator of future results.

19-1312 P-Brunner



# Valuation: Cyclically Adjusted PE Ratios



#### Index price to 10 year average real earnings per share

Valuations are recovering from Q4 but could be running ahead of earnings.

Source: AllianzGI, Bloomberg, as of April 01, 2019. All data taken from MSCI Indices except USA which uses S&P 500. Real EPS is computed by adjusting Earnings per Share for Ratios by the country's Consumer Price Index (CPI). 10 year average real EPS is computed using 40 quarters, or 20 semi-annual periods or 10 annual figures.



### Market outlook

#### Liquidity

- Ten years after the financial crisis, central banks have tentatively begun to normalise monetary policy
- Liquidity removal will eliminate and slowly reverse the main driver of asset returns over that period

#### Growth

- US fiscal stimulus has powered economic and earnings growth upwards but the incremental benefits are fading
- Economic indicators have been weakening, particularly in Europe and China, but may be stabilising at low levels
- Tariffs are negatively impacting global growth; domestic political pressure is growing in China and US to avoid further escalation
- Digitalisation is a long term structural change leading to increasing divergence in growth and stock performance

#### Valuation

- Valuations have become more attractive but remain higher than average historic range, particularly vs sales
- Higher volatility is offering opportunities to add to favoured stocks
- Balance sheet quality and strong cash-flow are regaining importance as the cost of leverage rises

Active management is required to navigate an increasingly uncertain market environment

#### Source: Allianz Global Investors, February 28, 2019



# The Cooper Companies

#### Specialist healthcare manufacturing



**Description:** A medical devices company, made up of Cooper Vision and Cooper Surgical. These specialise in the production of contact lenses and women's fertility devices, respectively.

**Quality:** CooperVision operates within a regulated, oligopolistic industry and has the leading market share in speciality lenses. Combined with its silicone hydrogel and daily lenses portfolio, Vision has consistently outperformed, gaining +1% market share annually since 2011. Although much smaller, CooperSurgical is using its scale and distribution capacity to consolidate and corner a relatively fragmented market. Result is two attractively growing businesses with good profitability.

**Growth:** COO has delivered 7% organic revenue growth and 12% adjusted EPS growth over the past five years. Contact lens market has grown 5-6% p.a. due to population growth, aging, aesthetics and pricing. By combining legacy gyno products with rapidly growing fertility segment, Surgical division expects c.4-5% growth. Overall steady growth of 5-6%.

**Valuation:** At the time of acquisition, COO traded at 17x next year's PE. This was low vs historic range due to competitive concerns. Given positive earnings revisions, we believe these are overdone.



# **Compass Group**

#### International Food Service Provider



**Description:** Compass is the world's largest food service provider. The company operates internationally, with a strong presence in the US and Europe. Serving public sector and business clients, Compass also runs franchises like Starbucks and Burger King under licence.

**Quality:** Compass has a track record of above-industry growth and profit margins thanks to its scale, superior execution and strategic reinvestments into profitable geographies and sub-segments. It also has first-mover advantage in the industry's most attractive market – the US. Efficiency improvements are steadily driving higher returns and the balance sheet is solid, with 1.5x net debt/EBITDA.


**Growth:** Outsourced food service is an underpenetrated market. Cost-cutting pressures in both corporate and public sectors is driving steady growth for large players, particularly in the US where 75% of the food service market is still fragmented. Historically, Compass has grown 4-6% p.a. thanks to organic growth and M&A.

**Valuation:** At the time of purchase, the stock was valued at c.17x next year's earnings. This valuation was depressed due to investor concern about a management transition. However, we believed this was misplaced, thus making for a good entry point.



### Informa

#### Global leader in exhibitions and media



**Description:** Informa's key business operations are in events and exhibitions, business intelligence and academic publishing. In January 2018, Informa announced its acquisition of UBM, creating the world's largest exhibitions company.

**Quality:** Exhibitions and Events are scalable high returns businesses with significant incumbent advantages. The combined entity should continue to reap the benefits of consolidating a fragmented industry with high barriers to entry. And, due to its capital-light business model, CFROI will be high at 40-50%.

**Growth:** The combination of UBM and Informa is expected to give organic revenue growth of 3-4%, with operating margins of c.32%. Exhibitions, which will drive 60% of Informa's post-UBM business, are free from structural risks and expected to grow at over 5% p.a. There are additional synergy benefits of c.£60m. Informa is also investing in its entire digital offering, such as SupplySide Connect or the New Hope Network. These services use Informa's extensive customer knowledge to deliver planning and consultancy, creating new revenue streams and customer insights for the business.

**Valuation:** When the deal was announced, shareholders were sceptical. Valuation was also depressed by scepticism over Informa's sector and domicile. As a result, Informa was added to the portfolio at around 15x P/E.



# **Agilent Technologies**

#### Global leader in life sciences and applied chemical markets



**Description:** Agilent provides core bio-analytical and electronic measurement solutions to the communications, electronics, life sciences, and chemical analysis industries.

**Quality:** Significant ongoing restructuring across Agilent divisions with a renewed emphasis on capital allocation and alignment with shareholder remuneration since appointment of new CEO in 2015.

**Growth:** Expected to grow around 5-6% towards USD5.1b revenues in 2020; CrossLab (laboratory productivity and missioncritical systems support, compliance) and diagnostics and genomics expected to be the strongest contributors. China +7% growth and international geographies are also growth contributors.

**Valuation:** On a valuation dispersion basis against instrumentation competitors Agilent remains slightly undervalued given the level of CFROI generation. On an intrinsic value basis, further revenue acceleration accompanied by margin expansion is anticipated for Agilent.



### **Ecolab services**

#### International water, hygiene and energy



**Description:** Ecolab provides solutions and on-site services to companies in a range of sectors. These range from the food and hospitality industry, to hospitals and energy companies.

**Quality:** Operating in a logistically and chemically complex sector creates high barriers to entry. Customer relationships are solid, with 90% of revenues on a recurring basis. Returns on capital are also consistently around 15% or higher.

**Growth:** Ecolab is a key beneficiary of a growing and aging global population. Its customers currently spend less than 1% of their budgets on cleaning and hygiene. It has also made \$600m of investment over the past 5 years in customer facing, field devices and infrastructure. This includes digitised online ordering and customer service. Expecting \$200m of efficiency savings by 2021 on top of customer knowledge from the data.

Valuation: At the time of purchase, the company was facing headwinds from a weak energy sector and rising input costs. Longer-term management expect to generate high single digit sales growth and double digit EPS growth. Over time, the company can use its brand strength to supplement this with acquisitions.

#### Allianz (1) Global Investors

# Why Brunner?



One of the highest yielding trusts in its sector with over 46 years of consecutive dividend growth

Long term outperformance vs benchmark

Optimal balance of global diversification and high conviction stock selection

An experienced team with a robust investment process

A discount that has narrowed thanks to debenture redemption, and potential for further reductions



#### Disclaimer

This is no recommendation or solicitation to buy or sell any particular security. Any security mentioned above will not necessarily be comprised in the portfolio by the time this document is disclosed or at any other subsequent date. Investment trusts are quoted companies listed on the London Stock Exchange. Their share prices are determined by factors including the balance of supply and demand in the market, which means that the shares may trade below (at a discount to) or above (at a premium to) the underlying net asset value.

The Trust seeks to enhance returns for its shareholders through gearing in the form of long-term debentures. Gearing can boost the Trust's returns when investments perform well, though losses can be magnified when investments lose value. You should be aware that this Trust may be subject to sudden and large falls in value and you could suffer substantial capital loss.

A trust's Net Asset Value (NAV) is calculated as available shareholders' funds divided by the number of shares in issue, with shareholders' funds taken to be the net value of all the company's assets after deducting liabilities. In line with current industry best practice NAVs are now shown that take into account the 'fair value' of debt. This means NAVs are calculated after allowing for the valuation of debt at fair value or current market price, rather than at final repayment value. NAVs with debt at market value provide a more realistic impact of the cost of debt, and thus a more realistic discount. It is the capital NAV that is shown, which excludes any income.

Investing involves risk. The value of an investment and the income from it may fall as well as rise and investors may not get back the full amount invested. The views and opinions expressed herein, which are subject to change without notice, are those of the issuer and/or its affiliated companies at the time of publication. The data used is derived from various sources, and assumed to be correct and reliable, but it has not been independently verified; its accuracy or completeness is not guaranteed and no liability is assumed for any direct or consequential losses arising from its use, unless caused by gross negligence or wilful misconduct. The conditions of any underlying offer or contract that may have been, or will be, made or concluded, shall prevail. Past performance is not a reliable indicator of future results.

The Trust is a UK public limited company traded openly on the stock market. A ranking, a rating or an award provides no indicator of future performance and is not constant over time. You can purchase shares through a stock broker. Shares in the Trust can be held within an ISA and/or savings scheme and a number of providers offer this facility. A list of suppliers is available on our website.

This is a marketing communication issued by Allianz Global Investors GmbH, an investment company with limited liability, incorporated in Germany, with its registered office at Bockenheimer Landstrasse 42-44, D-60323 Frankfurt/Main, registered with the local court Frankfurt/Main under HRB 9340, authorised by Bundesanstalt für Finanzdienstleistungsaufsicht (www.bafin.de). Allianz Global Investors GmbH has established a branch in the United Kingdom, Allianz Global Investors GmbH, UK branch, which is subject to limited regulation by the Financial Conduct Authority (www.fca.org.uk).

All data source Allianz Global Investors as at 31 October 2017 unless otherwise stated. Allianz Global Investors GmbH, UK Branch, 199 Bishopsgate, London EC2M 3TY



# **Active is:**

# Allianz Global Investors

The Brunner Investment Trust PLC

Annual General Meeting 4 April 2019

Lucy Macdonald Matthew Tillett







Value. Shared.



#### **Resolution 1:**

To receive and adopt the annual financial report

For	Discretion	Against	Withheld
16,385,126	31,612	0	5,724



#### **Resolution 2:**

To declare a final dividend

For	Discretion	Against	Withheld
16,387,792	31,612	0	3,058



#### **Resolution 3:**

To re-elect Vivian Bazalgette as a Director

For	Discretion	Against	Withheld
15,912,990	33,442	315,176	160,854



#### **Resolution 4:**

To re-elect Ian Barlow as a Director

For	Discretion	Against	Withheld
16,169,122	33,442	127,509	92,389



#### **Resolution 5:**

To re-elect Peter Maynard as a Director



#### **Resolution 6:**

To approve the Directors' Remuneration Implementation Report

For Discret	ion Against	Withheld
16,163,523 33,44	116,935	108,562



#### **Resolution 7:**

To re-appoint PricewaterhouseCoopers LLP as Auditor

For	Discretion	Against	Withheld
16,139,851	33,442	223,308	25,861



#### **Resolution 8:**

To authorise the directors to determine the remuneration of the Auditor

For	Discretion	Against	Withheld
16,298,089	33,442	44,742	46,189



#### **Resolution 9:**

To renew the directors' authority to allot ordinary shares

16,297,011 34,368 68,455 22,628



#### **Resolution 10:**

To disapply pre-emption rights

For	Discretion	Against	Withheld
15,839,307	34,368	476,470	72,317



#### **Resolution 11:**

To authorise the company to make market purchases of ordinary shares

For	Discretion	Against	Withheld
16,100,607	33,538	240,605	47,712



# **Active is:**

# Allianz Global Investors